ACell, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| ACell, Inc. | ACLL - NASDAQ |
$14.00-$16.00 | $0.00 | $0.00 | 5 million | |
| UBS Investment Bank, Barclays, RBC Capital Markets | ||||||
Co-Manager(s): SunTrust Robinson Humphrey | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-06-26 Terms Added 2020-01-01 | ||||||
About ACell, Inc. (adapted from ACell, Inc. prospectus):
They are a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ACLL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.